Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Co-Diagnostics (NASDAQ: CODX) signed a definitive joint venture agreement with Arabian Eagle to form CoMira Diagnostics in the Kingdom of Saudi Arabia to research, develop, manufacture, assemble, distribute, and commercialize Co-Dx technologies across KSA and 18 additional MENA countries. CoMira will pursue SFDA clearance to facilitate regional market entry and receive an exclusive license to manufacture and commercialize Co-Dx IP, including the upcoming Co-Dx PCR point-of-care platform. Infectious-disease tests slated for clinical evaluations before the end of 2025 include tuberculosis, an 8-type HPV multiplex, and a respiratory multiplex for influenza A/B, COVID-19, and RSV. The platform remains subject to regulatory review and is not yet available for sale.
Co-Diagnostics (NASDAQ: CODX) said its executive leadership team will attend and host a booth at Global Health Exhibition 2025 in Riyadh, KSA, on October 27–30, 2025. Attendees listed include CEO Dwight Egan, President Richard Abbott, Chief Commercialization and Strategy Officer Seth Egan, other department heads, and board member Eugene Durenard.
The company will showcase its Co-Dx infectious disease PCR products and the upcoming Co-Dx PCR point-of-care platform at Booth #H3.L17. The announcement follows a September 16 MOU exploring a joint venture to develop, manufacture, and sell Co-Dx IP across the Middle East and North Africa. The Co-Dx PCR platform is subject to regulatory review and not available for sale.
Co-Diagnostics (Nasdaq: CODX) announced development of a proprietary sample preparation instrument for its point-of-care Co-Dx PCR MTB test, designed for low-cost, user-friendly sample processing in resource-limited settings. The device supports sputum and a novel tongue swab method, uses single-button operation with no measuring tools, and includes a built-in safety feature to inactivate live organisms. Clinical evaluations in India for the MTB test are expected to begin before year-end 2025. Manufacturing is anticipated with Systronics under India’s "Make in India" initiative.
Co-Diagnostics (Nasdaq: CODX) announced it will participate in the 2025 Maxim Growth Summit on October 22-23 at The Hard Rock Hotel NYC. The company said it will hold one-on-one meetings with institutional investors and meet with senior Maxim analysts during the event.
The summit features keynote speakers Larry Kudlow and Christopher Ruddy, roundtable discussions across sectors including biotechnology and artificial intelligence, and sessions moderated by Maxim Research Analysts. For agenda details, attendees are directed to the Maxim Growth Summit website.
Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, announced its participation in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will deliver a webcast presentation at 4:15 p.m. ET and conduct one-on-one meetings with institutional investors.
The presentation will be accessible through the conference website and will be available for replay afterward. Investors can find the presentation slides on the company's investor relations website and schedule one-on-one meetings through Lytham Partners.
Co-Diagnostics (NASDAQ:CODX) has completed its previously announced registered direct offering, raising $3.8 million in gross proceeds. The offering involved the sale of 9,619,000 shares of common stock priced at $0.40 per share, conducted at-the-market under Nasdaq rules.
The company plans to utilize the proceeds for working capital and general corporate purposes. Maxim Group LLC served as the sole placement agent for the offering, which was executed under an effective shelf registration statement on Form S-3.
Co-Diagnostics (NASDAQ:CODX) has announced a registered direct offering of 9,619,000 shares of common stock priced at $0.40 per share, aiming to raise approximately $3.8 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules and is expected to close around September 18, 2025.
The molecular diagnostics company plans to use the proceeds for working capital and general corporate purposes. Maxim Group LLC is serving as the sole placement agent for the offering, which is being conducted under an effective S-3 shelf registration statement.
Co-Diagnostics (NASDAQ:CODX) has signed a strategic Memorandum of Understanding (MOU) with a partner in Saudi Arabia to establish a joint venture for manufacturing and distributing its Co-Dx™ PCR platform across the Middle East and North Africa (MENA) region.
The planned JV aligns with Saudi Arabia's Vision 2030 initiatives and follows a similar model to CODX's Indian joint venture, CoSara Diagnostics. The Saudi partner will provide local operational support, infrastructure, personnel, and regulatory expertise throughout the MENA region. Saudi Arabia represents one of the largest international markets for CODX's Logix Smart® tests.
The Co-Dx PCR platform, including PCR Home™ and PCR Pro™, is currently pending regulatory review and is not yet available for sale.
Co-Diagnostics (NASDAQ:CODX) has completed an in silico analysis of its Co-Primers®-based PCR tests for chikungunya virus (CHIKV) detection. The analysis demonstrated high homology against over 1,200 CHIKV sequences and confirmed reactivity against recent virus strains.
The company's Logix Smart® ZDC Test, CE-marked since 2019, can detect and differentiate between Zika, dengue, and chikungunya viral RNA. Additionally, CODX's Vector Smart® VZDC Test is used by 30 mosquito abatement districts across 20 U.S. states for environmental testing. The company's Indian joint venture, CoSara Diagnostics, has received clearance to manufacture and sell its SaraGene™ Dengue and Chikungunya Multiplex RT-PCR test.
Co-Diagnostics (NASDAQ:CODX) has been recognized at the Utah Business 2025 Innovation Awards Summit for its Co-Dx PCR platform in the Healthcare and Life Sciences category. The platform, which includes the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and associated tests and software, was honored for its innovative approach to molecular diagnostics.
CEO Dwight Egan accepted the award, highlighting the company's commitment to expanding access to high-quality PCR diagnostics globally. The platform is currently pending regulatory review by the FDA and other bodies, with commercialization expected in 2026.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
